Figure 1

![Figure 1: Initial experimental data from a study on liraglutide's promotion of diabetic wound healing via the Myo1c/Dock5 signaling pathway. Wound closure rates or cellular migration measurements are presented for diabetic versus control conditions.]()

> Source: Qian Zhang et al. "Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.." *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 2024. PMID: [39159301](https://pubmed.ncbi.nlm.nih.gov/39159301/)

<figure>
  <img src="" alt="Initial experimental data from a study on liraglutide's promotion of diabetic wound healing via the Myo1c/Dock5 signaling pathway. Wound closure rates or cellular migration measurements are presented for diabetic versus control conditions." />
  <figcaption>Figure 1. Initial experimental data from a study on liraglutide's promotion of diabetic wound healing via the Myo1c/Dock5 signaling pathway. Wound closure rates or cellular migration measurements are presented for diabetic versus control conditions.<br>  Source: Qian Zhang et al. "Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.." <em>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</em>, 2024. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39159301/">39159301</a></figcaption>
</figure>